{
    "root": "de559204-8191-4de6-93f7-b817cb6d9d6f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fenofibrate",
    "value": "20250328",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        }
    ],
    "indications": "fenofibrate tablets peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet : \u2022 reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . \u2022 treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
    "contraindications": "\u2022 primary hypercholesterolemia mixed dyslipidemia : initial dose 145 mg daily ( 2.2 ) . \u2022 severe hypertriglyceridemia : initial dose 48 145 mg daily . maximum dose 145 mg ( 2.3 ) . \u2022 renally impaired patients : initial dose 48 mg daily ( 2.4 ) . \u2022 geriatric patients : select dose basis renal function ( 2.5 ) . \u2022 maybe taken without regard meals ( 2.1 ) .",
    "warningsAndPrecautions": "fenofibrate tablets , usp 145 mg white off-white , oval-shaped , biconvex , film-coated tablets debossed \u2018 rh38 \u2019 one side side ndc : 71335-0872-1 : 30 tablets bottle ndc : 71335-0872-2 : 90 tablets bottle ndc : 71335-0872-3 : 28 tablets bottle storage store 20\u00ba - 25\u00ba c ( 68\u00ba - 77\u00ba f ) [ usp controlled room temperature ] . keep reach children . protect moisture . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "fenofibrate contraindicated : \u2022patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . \u2022patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.2 ) ] . \u2022patients preexisting gallbladder disease [ ( 5.5 ) ] . \u2022nursing mothers [ ( 8.2 ) ] . \u2022patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "indications_original": "Fenofibrate tablets are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: \u2022 To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (1.1). \u2022 For treatment of adult patients with severe hypertriglyceridemia (1.2). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus (5.1).",
    "contraindications_original": "\u2022 Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily (2.2). \u2022 Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg (2.3). \u2022 Renally impaired patients: Initial dose of 48 mg once daily (2.4). \u2022 Geriatric patients: Select the dose on the basis of renal function (2.5). \u2022 Maybe taken without regard to meals (2.1).",
    "warningsAndPrecautions_original": "Fenofibrate tablets, USP\n                  \n                  \n                     145 mg white to off-white, oval-shaped, biconvex, film-coated tablets debossed with \u2018RH38\u2019 on one side and other side\n                  NDC: 71335-0872-1: 30 Tablets in a BOTTLE\n                  NDC: 71335-0872-2: 90 Tablets in a BOTTLE\n                  NDC: 71335-0872-3: 28 Tablets in a BOTTLE\n                  \n                     Storage\n                  \n                  Store at 20\u00ba - 25\u00ba C (68\u00ba - 77\u00ba F) [See USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.\n                  Burbank, CA 91504",
    "adverseReactions_original": "Fenofibrate is contraindicated in:\n                  \n                     \n                        \u2022patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].\n                     \n                        \u2022patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].\n                     \n                        \u2022patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].\n                     \n                        \u2022nursing mothers [see Use in Specific Populations (8.2)].\n                     \n                        \u2022patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)]."
}